Mobile

A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an alte...

Update Il y a 4 ans
Reference: EUCTR2005-000362-39

A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an alternative to irbesartan in Type 2 patients with incipient/overt diabetic nephropathy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

• To investigate whether renin-inhibition using Aliskiren 300 mg daily could be a treatment alternative to the angiotensin II receptor antagonist Irbesartan 300 mg with an equivalent potential for renoprotection

Inclusion criteria

  • Hypertension

Links